Company news
Immutep Ltd news in 2017
Immutep Ltd's news releases, calls and decks from 2017, newest first.
European patent grant for IMP321 in cancer
November 21, 2017
Japanese Patent Grant for IMP731 Antibody
September 8, 2017
Japanese Patent Grants For IMP321 In Infectious Disease
September 5, 2017
PRR & Monash Uni receive funding grant for LAG-3 Research
August 30, 2017
Appendix 4E & 2017 Full Year Statutory Accounts
August 28, 2017
French government research cash rebate of A$1.3M received
August 16, 2017
Financial Update
July 17, 2017
2nd milestone payment to be received from Novartis
July 16, 2017
Approvals received to initiate INSIGHT clinical trial
July 10, 2017
Disclosure Under LR 3.10.5A and 7.1A.4(b)
July 5, 2017
Form 6-K
June 30, 2017
USD 5 Million Capital Raising
June 29, 2017
IMP321 demonstrates positive safety & efficacy qualities
June 4, 2017
Approval received to commence 3rd cohort of melanoma trial
April 19, 2017
$492k R&D Tax Incentive Refund Received
April 12, 2017
PRR completes recruitment for 2nd patient cohort
March 14, 2017
US patent granted for IMP321
March 1, 2017
French Research Tax Credit Payment Received
February 13, 2017
PRR commences randomised phase IIb clinical trial
January 19, 2017
Prima commences recruitment for 2nd cohort of melanoma trial
January 11, 2017
Prima Enters New MTA with CYTLIMIC
January 5, 2017
Prima announces new LAG-3 agonist antibody product candidate
January 2, 2017
Decks in 2017
- Prima BioMed — Shareholder Meeting (November 2017)
Shareholder meeting · 26 slides · Nov 20, 2017
- Prima BioMed — Investor Presentation (January 2017)
Investor deck · 36 slides · Jan 9, 2017